Acurx Pharmaceuticals, Inc.

Another big batch of biopharmaceutical company initial public offerings in the US brings the 2021 total to 60 IPOs as drug developers continue to take advantage of the rising valuations that the indus

Initial public offerings by biopharmaceutical companies are back on an above-average track after eight firms went public in the US during the week of 14 to 18 June, raising $1.46bn combined, including